Aytu Biopharma (AYTU) Q4 2024 earnings summary

Executive summary

• Repositioned as a specialty pharmaceutical company focused on ADHD and pediatric portfolios, exiting clinical development and consumer health businesses to improve cash flow and profitability.

• Fiscal 2024 consolidated net revenue was $81M, down from $107.4M in 2023, reflecting the consumer health wind-down and pediatric portfolio decline.

• ADHD Portfolio net revenue grew 23% to $57.8M, while the Pediatric Portfolio declined due to payor changes.

• Adjusted EBITDA improved 162% to $9.2M in fiscal 2024 from $3.5M in 2023, with the Rx Business contributing $10.8M.

• Consumer Health Segment was fully divested in July 2024, securing up to $500K in future royalty payments and aligning with the strategic focus on higher-margin prescription therapeutics.

Financial highlights

• Fiscal 2024 net revenue was $81M, down from $107.4M in 2023, due to the consumer health wind-down and pediatric portfolio decline.

• ADHD portfolio revenue grew 23% year-over-year to $57.8M, offsetting a pediatric revenue drop to $7.3M from $25.4M.

• Company-wide gross margin improved to 67% from 62% last year; Rx segment gross margin reached 75%.

• Net loss narrowed to $15.8M ($2.86/share) from $17.1M ($5.11/share) in 2023; Adjusted EBITDA rose to $9.2M from $3.5M.

• Cash and equivalents at June 30, 2024, were $20M, stable from prior quarters.

Outlook and guidance

• Management expects Rx Segment net revenue and Adjusted EBITDA in fiscal 2025 to exceed 2024 levels.

• Early fiscal 2025 shows strong ADHD and pediatric unit growth, with pediatric shipments up 115% and ADHD units up 26% since July 1.

• Confident in returning pediatric products to meaningful revenue contribution, with commercial initiatives and improved payer coverage underway.